Clinical trials: Primary Antiphospholipid Syndrome
Antiphospholipid Syndrome (APS)
Effect of Belimumab on Antibody Titers in Primary APS Patients
The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.
- Trial name
- NCT06747312
- Testing
- Belimumab+SOC, SOC
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Preeclampsia, Immunologic Disease
Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome
The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS.
- Conditions
- Preeclampsia, Immunologic Disease, Antiphospholipid Antibody Syndrome Primary, Pregnancy Complications
- Trial name
- NCT05786235
- Testing
- Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Antiphospholipid Syndrome
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in…
- Trial name
- MONOCYTAN (NCT06373926)
- Testing
- blood withdrawal
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Antiphospholipid Syndrome (APS)
Effect of Telitacicept on Antibody Titers in Primary APS Patients
The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.
- Trial name
- NCT06315530
- Testing
- Telitacicept+SOC, SOC
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital